These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Development of Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889 [TBL] [Abstract][Full Text] [Related]
11. Single Chelator-Minibody Theranostic Agents for Ho KV; Tatum DS; Watkinson L; Carmack T; Jia F; Mascioni A; Maitz CA; Magda D; Anderson CJ J Nucl Med; 2024 Sep; 65(9):1435-1442. PubMed ID: 39142831 [TBL] [Abstract][Full Text] [Related]
12. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate. Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845 [TBL] [Abstract][Full Text] [Related]
13. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting. Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611 [TBL] [Abstract][Full Text] [Related]
14. Hetero-bivalent agents targeting FAP and PSMA. Boinapally S; Lisok A; Lofland G; Minn I; Yan Y; Jiang Z; Shin MJ; Merino VF; Zheng L; Brayton C; Pomper MG; Banerjee SR Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4369-4381. PubMed ID: 35965291 [TBL] [Abstract][Full Text] [Related]
15. Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors. Vaidyanathan G; Kang CM; McDougald D; Minn I; Brummet M; Pomper MG; Zalutsky MR Nucl Med Biol; 2018; 62-63():18-30. PubMed ID: 29803076 [TBL] [Abstract][Full Text] [Related]
17. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Benešová M; Umbricht CA; Schibli R; Müller C Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475 [TBL] [Abstract][Full Text] [Related]
18. Lee BS; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim MH; Kim MH; Chi DY; Ahn H; Lee YJ; Lee KC; Lim SM Prostate; 2020 Dec; 80(16):1383-1393. PubMed ID: 32960990 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and pre-clinical evaluation of a new class of high-affinity Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991 [TBL] [Abstract][Full Text] [Related]
20. PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic. Huang B; Otis J; Joice M; Kotlyar A; Thomas TP Biomacromolecules; 2014 Mar; 15(3):915-23. PubMed ID: 24392665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]